Putting the bits and pieces of the RET proto-oncogene puzzle together.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 8579892.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The RET proto-oncogene has been implicated in the causation of papillary thyroid carcinoma, multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B), and Hirschsprung's disease. The mutations in these syndromes can be categorized into activating or inactivating mutations. Activating mutations of a cysteine-rich extracellular region cause enhanced dimerization of the RET tyrosine kinase receptor and autophosphorylation, and are causative for MEN 2A and familial medullary thyroid carcinoma (FMTC). An activating mutation of the tyrosine kinase domain causes increased autophosphorylation but does not affect the state of dimerization. A variety of inactivating mutations of the RET proto-oncogene, which result in defective protein formation, are causative for Hirschsprung's disease.
Medical subject headings
- Drosophila Proteins
- Gene Expression
- Multiple Endocrine Neoplasia Type 2a
- Multiple Endocrine Neoplasia Type 2b
- Point Mutation
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases